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Abstract
Background: Diabetes mellitus is a metabolic disorder which is rising globally in rich and developing countries. In
the African region this rate is the highest, with 20 million diagnosed diabetics. Despite a noticeable progress in the
treatment of diabetes mellitus by synthetic drugs, the search for new natural anti-diabetic agents is going on.
Nauclea diderrichii (De Wild.) Merr. (ND) and Sarcocephalus pobeguinii Hua ex Pellegr. (SP) are used as traditional
medicines in Gabon for the treatment of different diseases, especially in the case of diabetes. The aim of this study
was to evaluate the antidiabetic potential of these two medicinal plants traditionally used in Gabon.
Methods: Pharmacological (inhibitory action on α and β-glucosidases) and toxicological (effect on human T cell
proliferation) studies were conducted on aqueous extracts of ND (leaves and bark) and SP (bark) collected in Gabon.
All raw extracts were analyzed by HPTLC and their content in phenolic compounds was determined by using
standard method. The most active extracts were submitted to preparative HPLC in order to evidence the most
efficient subfractions by biological evaluation.
Results: The results showed that two extracts from ND were potent α-glucosidase inhibitors, the leaf extract being
more active that the bark extract: the first one was more than 60 fold more active than Acarbose, which is an oral
medication used to treat type 2 diabetes; the extract from SP bark was less efficient. The HPLC subfractions of the
extracts of ND leaves and SP bark were tested in the same experimental conditions. In each case, the most active
subfractions still show very potent inhibitory effect on α-glucosidase (80-90 % inhibition at 0.1 mg/mL). The most
efficient extract, from ND leaves, was also characterized by the highest percentage of phenolic compounds, which
suggests a relationship between its inhibitory potential on α-glucosidase and its content in phenolic compounds.
Conversely, only a moderate inhibitory activity of the three extracts was observed on β-glucosidase.
Conclusion: These results clearly indicated that active compounds present in N. diderrichii and S. pobeguinii leaves
or/and bark were selective and highly potent inhibitors of α-glucosidase and validate their popular use for the
treatment of diabetes.
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Background
Diabetes mellitus is a metabolic disorder, mainly of two
types (1 and 2) and characterized by chronic hypergly-
cemia with disturbances of carbohydrate, fat and protein
metabolism resulting from defects in insulin secretion,
insulin action or both [1–3]. Currently, the number of
diabetics sharply increases in rich and developing
countries. In 2013, the overall prevalence of diabetes in
the world’s population was estimated to 8.3 % approxi-
mately [4]. In the African region, and particularly in
Sub-Saharan Africa, this rate is the highest, with 20 mil-
lion diagnosed diabetics [5].
Oral hypoglycemic agents, such as α-glucosidase in-
hibitors, exert their effects via a variety of mechanisms,
which include the reduction of hepatic glucose produc-
tion, the enhancement of insulin secretion by pancreatic
β-cells and the improvement of insulin sensitivity. Glu-
cosidase inhibitors have been the subject of extensive
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interest [6] because of their potential as drugs for the treat-
ment of diabetes [7]. Alpha-glucosidase is a membrane-
bound enzyme, at the epithelium of the small intestine; it
hydrolyses the cleavage of glucose from disaccharides and
oligosaccharides. The inhibitors of this enzyme delay
carbohydrate hydrolysis, prolong the overall carbohydrate
digestion time and thus cause a reduction in glycaemia [8].
Therefore, inhibition of α-glucosidase is considered as an
important way to treat non-insulin-dependent diabetes.
This hypothesis was successfully confirmed in animal and
clinical studies by the administration of various α-
glucosidase inhibitors [9, 10].
Despite considerable progress in the treatment of dia-
betes mellitus by synthetic drugs, the search for new natural
anti-diabetic agents is going on. The world health
organization (WHO) estimates that 80 % of the population
in some developing countries, especially in Sub-Saharan
Africa, still use the traditional medicine [11]. Several plants
are used in folk medicine for their hypoglycemic activity
and they were investigated using different experimental
methods [12]. Thanks to these studies, natural glycosidase
inhibitors have been discovered and tested for their activity
[13, 14].
Gabon has remarkable biodiversity and rich cultural tra-
ditions of plant use. Scientific understanding of medicinal
plants is however largely unexplored and pharmacological
investigation of Gabonese flora only gained momentum re-
cently. Rubiaceae are among plants of wide usage in trad-
itional medicine in the Sub-Saharan region [15] more
particularly Nauclea and Sarcocephalus species, which be-
long to the tribe Naucleae, subtribe Naucleinae [16]. In
Gabon, the species Nauclea diderrichii and Sarcocephalus
pobeguinii (syn. Nauclea pobeguinii) are used in folk medi-
cine for the treatment of different diseases, especially in the
case of diabetes associated or not to hypertension. In the
Eviya area, S. pobeguinii is also used in leaf infusions as feb-
rifuge, while bark maceration is indicated for urogenital in-
fections [17]. The traditional use of both species is also
mentioned in ethnomedicinal reports from other African
countries: N. diderrichii is used in Nigeria against arthritis
and malaria [18, 19] while S. pobeguinii was reported for
several indications in Cameroon [20], Nigeria [21, 22],
Guinea [23] and Senegal [24].
N. diderrichii is an evergreen tree that reaches a
height of 30-40 m and a diameter of 0.9-1.5 m; its
natural habitat is subtropical or tropical moist low-
land forests; the wood of this tree, which is known as
bilinga, is dense and resistant to fungi and insects
[25]. S. pobeguinii is a forest tree or shrubby tree 6–30 m
tall; its bark is whitish, grey or pale brown, roughly
fissured, flaking in papery scales about 2 cm in diameter;
its fruits are edible [26].
The chemical investigations on these two species are
numerous: they concern alkaloids from N. pobeguinii
[27, 28] whereas alkaloids [29–31], saponins [32, 33] and
other chemical classes [34, 35] were obtained from differ-
ent plant parts of N. diderrichii. A few biological studies
have been conducted on these species. Water or/and ether
extracts of N. diderrichii from Gabon were evaluated for
their anti-malarial [36] and anti-leshmanial [37] activities.
The same species collected in the West African region
was screened for its antiplasmodial activity [38].
Finally, ethanol extracts from N. pobeguinii bark were
also tested for their antimalarial activity [39–42].
Nevertheless, to the best of our knowledge, N.diderri-
chii and S. pobeguinii were not screened for their
hypoglycemic activity despite their traditional use for
diabetes. A literature survey shows only some studies in
this field on plants belonging to the same genera, such
as Sarcocephalus latifolius from the Central Region of
Togo [43] and Nigeria [44] or Nauclea latifolia collected
in Benin (roots and stem) [45] or in Nigeria (leaves)
[46]. This led us to carry out phytochemical and bio-
logical investigations on the two species collected in
Gabon: bark and leaf extracts of N. diderrichii as well as
bark extract of S. pobeguinii.
Plant extracts were prepared and tested in human cells
to determine their capacity to inhibit α- and β-
glucosidases, to investigate their biocompatibility with
cells and to provide pharmacological basis for their trad-
itional use as anti-diabetic agent.
Methods
Plants materials
The plant selection was based on their use by local
population and traditional healers. Thirty people were
interviewed in 10 villages located in the Nkomo Mondah
department (Province de l’Estuaire), in the Ogooué as
well as in the Lakes departments (Province du Moyen
Ogooué). These data were supplemented by literature
information [17, 23, 47–49]. The plants were collected
during the short dry season: N. diderrichii was collected
in Libreville in December 2009 (department of Nkomo-
Mondah) and S. pobeguinii was collected in Lambarene
in January 2010 (department of Ogooue). They were
identified by Y. Issembe and R. Niangadouma, botanists
at the National Herbarium of the Institute of Pharmaco-
pea and Traditional Medicine (IPHAMETRA) where
voucher specimens were deposited under the following
numbers: Nauclea diderrichii (De Wild.) Merr. [Wilks:
8836 (WAG), 1988; 2438 (LBV, WAG), 1991] and Sarco-
cephalus pobeguinii Hua ex Pellegr. [Azizet Issembé 172
(LBV, WAG), 2000; Wilks: 1035 (LBV, WAG)]. Leaves
and bark of N. diderrichii as well as bark pieces of S.
pobeguinii were collected and air dried in a room main-
tained at a controlled temperature (25 °C) using an air-
conditioning unit; then, the samples were stored in a dry
place until use.
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Preparation of plants extracts
In the case of N. diderrichii, two parts of the plant were
extracted: raw leaves and ground bark. Plant material
was macerated in water (100 g of plant sample in 1 L of
water at room temperature). After filtration on büchner
(paper Whatman N°3, medium porosity, particle reten-
tion 6 m, diam. 9 cm), the filtrates were lyophilized to
give the samples E 14 (leaves) and E 15 (bark) with
13.9 % yield and 15.0 % yield respectively. The ground
bark of S. pobeguinii was extracted by decoction. Briefly,
100 g of plant material was boiled in 1 L of water for
30 min. After filtration on paper Whatman N°3 (medium
porosity, particle retention 6 m, diam. 9 cm), the
filtrate was cooled at room temperature and lyophilized
to obtain 10.34 g of the extract E 10.
Phytochemical analysis by HPTLC
Phytochemical analysis of the extracts was undertaken
by HPTLC method using HPTLC plate silica gel F254s
(Merck) 20×10 cm and different derivatizations. All re-
agents and solvents were of analytic grade.
The samples were tested following the CAMAG Stand-
ard Operating Procedures (SOP): 200 mg of dry extracts
were dissolved in 10 mL of ethanol:water 1:1, sonicated
twice during 10 min and centrifuged. The supernatant
was used for the analyses; applications volumes: 2 and/or
5 L for samples and standard solutions with Automated
TLC Sampler 4, band length 8 mm, distance from lower
edge 8 mm, distance from left and right edge 20 mm,
track distance min. 10 mm; development in the Automatic
Developing Chamber ADC2 with chamber saturation dur-
ing 20 min and with adjustment of relative humidity to
33%rH. The migration distance (from lower edge of plate)
was 70 mm; different mobile phases and derivatization
reagents were used: S1 (toluene : ethyl acetate 19:1), S2
(chloroform : methanol : water 35:15:2), S3 (ethyl acetate :
acetic acid : formic acid : water100:11:11:27), S4 (1-buta-
nol : acetic acid : water 7:1:2) and S5 (chloroform : metha-
nol : water 70:30:4).
The most suitable solvent system combined with the
adequate derivatization was selected for the perform-
ance: the best resolution was most often observed with
mobile phases S2 and S3 for N. diderrichii and mobile
phase S2 in the case of S. pobeguinii.
The HPTLC plates were dipped in the following deriv-
atization reagents:
– Anisaldehyde sulphuric acid reagent (AAS) (for
mobile phases S1, S2 and S4) for saponins detection
under white light
– NP/PEG reagent (S3) for flavonoids detection under
366 nm
– Dragendorff reagent (S5) for alkaloids detection
under white light
– 2,2-Diphenyl-picrylhydrazyl reagent (DPPH) for
screening of antioxidant properties of substances (S3).
Observation was performed using TLC Visualizer
under UV 254 and 366 nm prior to derivatization and
under UV 366 nm and white light illumination (remis-
sion and transmission mode) after derivatization.
Determination of total phenolic compound content
Folin-Ciocalteu reagent F 9252 lot # BCBF 2476 was
purchased from Sigma-Aldrich Co (France). Total phe-
nols content was performed by the Folin-Ciocalteu (FC)
colorimetry method (FC) [50] which is based on a chem-
ical reduction of the reagent, a mixture of tungsten and
molybdenum oxides. Although not very specific for phe-
nolics, the protocol gives a good idea of the total phe-
nols content. Gallic acid was employed as calibration
standard and results were expressed as gallic acid equiva-
lents. Briefly, 0.5 mL of gallic acid solution (10-100 mg/L)
was mixed with 0.25 mL FC reagent (1 N). After five mi-
nutes, 1.25 mL sodium carbonate (20 % w/v) was added.
The mixture was shaken and left during one hour at room
temperature. Absorbance A was measured at 725 nm with
different concentrations (c) of gallic acid. The linear re-
gression A = f(c) was carried out with Microsoft Excel.
The same protocol was used with the plants extracts
(0.2-1 g/L) to evaluate their phenols content. The re-
sults were expressed in mg of gallic acid equivalents
(GAE) per g extract. All experiments were repeated
three times. The results are expressed as the mean ±
standard deviation (SD).
Fractionation by HPLC
The HPLC purifications were run on a Waters 4000 pre-
parative apparatus on a C18 Deltapak column (100 mm ×
40 mm, 15 m, 100 Å), with UV detection at 214 nm, at a
flow rate of 50 mL/min of a mixture of A (water with
0.1 % TFA) and B (acetonitrile with 0.1 % TFA) in a gradi-
ent mode. E 10 was purified starting from 100 % A to
100 % B in 20 min after an isocratic run of 5 min in 100 %
A. E 14 was purified in a gradient mode from 100 % A to
50 % B in 25 min. The samples were collected manually
every two minutes and the fractions were lyophilized.
α-Glucosidase and β-glucosidase inhibitory assays
Acarbose, α-glucosidase from Saccharomyces cerevisiae
and β-glucosidase from almond were obtained from
Sigma, isofagomine was synthesized as previously reported
[51]. Typical procedure for inhibition studies: α- and β-
glucosidase activities were assayed with either 8 mM
solution of 4-methyl umbelliferyl α-D-glucopyranoside
or 4-methyl-umbelliferyl β-D-glucopyranoside (Carbo-
synth) in 100 mM NaHPO4 buffer, pH 6.8 at 30 °C in a
384-well microplate. 10 mM Acarbose and 1 M
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isofagomine were used as reference inhibitors for α-
and β-glucosidases, respectively. Fluorescence was
monitored ( excitation = 364 nm, emission = 445 nm) over
a 20 min period, in the presence of the extract/com-
pound solutions in DMSO compared to the same vol-
ume of DMSO alone. The fluorescence increase
reflected the cleavage of umbelliferyl glucopyranosides:
the value 100 % was attributed to the fluorescence ob-
tained with enzymes in the presence of DMSO alone.
In incubations with extracts or compounds, remaining
activity (RA, expressed as a percentage) was calculated
as the ratio [fluorescence released in the presence of
extracts/compounds]/[fluorescence released in the
presence of DMSO alone] × 100 and shown in Figs. 2,
3, 4 and 5 for every concentration of extract/com-
pound. Finally, the percentage inhibition was calculated
from these values following the equation: 100-RA.
For the initial screening, extracts dissolved in DMSO
were added at a final concentration of 1 mg/mL. Active
extracts and separated fractions were diluted in DMSO
and added at concentrations ranging 0.01 to 1 mg/mL
in duplicate.
Cell culture and cytotoxicity assay
Human breast (MCF-7) cancer cells were purchased
from ATCC (American Type Culture Collection, Manas-
sas, VA). MCF-7 cells were cultured in DMEM-F12 cul-
ture medium supplemented with 10 % foetal bovine
serum and gentamycin 50 g/mL. These cells were
allowed to grow in humidified atmosphere at 37 °C
under 5 % CO2. For cytotoxicity analysis, MCF-7 cells
were seeded into 96-well plates at 2.104 cells per well in
200 L culture medium and allowed to grow for 24 h.
Then cells were treated for 48 h with or without extracts
at 0.5 and 1 mg/mL. After incubation, a MTT assay was
performed to evaluate the cytotoxicity [52]. The assay
detects the reduction of MTT [3-(4,5-dimethylthiazolyl)-
2,5-diphenyl-tetrazolium bromide] by mitochondrial de-
hydrogenase to blue formazan products, which reflects
the normal functioning of mitochondrial and cell viabil-
ity [53]. Briefly, 0.5 mg/mL MTT reagent (20 L) was
added to each well and incubated for additional 4 h.
Then, the medium was removed and 150 L of EtOH/
DMSO (1:1) was added to MTT precipitates in each well
to solubilize the formazan crystals. The plates were read




Of all the collected information, it appears firstly that
populations refer to the experiences of others to use me-
dicinal plants as a remedy against well-defined diseases
in accordance with a transmission of traditional
practices from one generation to another, or refer to
traditional healers. Usually, the dose remains uncertain. In
addition, the traditional healers do not generally identify
stricto sensu the diabetic or hypertensive pathology, but
they treat the characteristic symptoms associated with
them. Among all the data, S. pobeguinii and N. diderrichii
were the most cited for the various therapeutic applica-
tions mentioned above, and ethnobotanical survey
reported the use of macerate or decoction of bark of both
species to cure diabetes as well as hypertension. Finally,
these species were harvested in their natural habitat.
Chemical screening
The phenols content of the three extracts obtained from
the equation A = 19.392c − 0.0153 (in which A repre-
sents the absorbance and c the gallic acid concentration,
in g/L) were expressed as gallic acid equivalent (GAE)
by gram of extract as follows:
E 10 = 84.5 mg ± 1.5 GAE/g extract
E 14 = 148 mg ± 3 GAE/g extract
E 15 = 75.2 mg ± 2.6 GAE/g extract
Extract 14, obtained from N. diderrichii leaves, is charac-
terized by the highest percentage of phenolic components
Table 1 Phytochemical test results by HPTLC of S. pobeguinii
and N. diderrichii extracts




+ ++ + +
N. diderrichii leaf
(E14)
+ + ++ ++
N. diderrichii bark
(E15)
+ + ++ +
Sign (+) indicates present (++ for more intense zones) and sign (-)
indicates absent
Fig. 1 Cytotoxicity of extracts 10, 14 and 15 on the human cell line
MCF-7. Cells were incubated or not (Control) with 0.5 or 1 mg/mL of
each extract for 48 h. Cell viability was quantified by MTT assay. Data
are mean ± SD of 2 independent experiments
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while both extracts from bark of N. diderrichii (E 15) and
S. pobeguinii (E 10) contained lower amounts of com-
pounds belonging to this chemical class. These results are
corroborated by the HPTLC analysis using DPPH reagent
which shows some nice defined white zones for the three
extracts, mainly in the case of E14, indicating a high radical
scavenging effect, mainly located in the polar fraction (see
Additional file 1).
The other HPTLC experiments using different deriva-
tization reagents (HPTLC plates not shown) revealed
the presence of flavonoids, alkaloids and saponosids in
the extracts (Table 1). These results confirm the litera-
ture data which report the presence of alkaloids, flavo-
noids, steroids and glycosides [27, 28] in S. pobeguinii.
The isolation of alkaloids and saponins (quinovic acid
glycosides) from N. diderrichii has also been reported
[29–34].
Cytotoxicity evaluation
Finally, in order to verify the safety of these extracts,
cytotoxicity experiments were performed on human
MCF-7 cell line. Cells were incubated 48 h with the
extracts 10, 14 and 15 previously dissolved in
phosphate buffer, at final concentrations of 0.5 and
1 mg/mL. Cell viability results are represented in
Fig. 1. Compared to the control incubated with phos-
phate buffer alone, there is no decrease in the num-
ber of living cells after treatment with E 10, E 14 and
E 15. Data show that, in the conditions used in this
study, no cytotoxicity was observed on human cells
treated with the extracts 10, 14 and 15. However, this
Fig. 2 Inhibition of α-glucosidase by extracts 10, 14 and 15. α-Glucosidase was incubated with extracts at a concentration of 1 (panel a) and
0.1 mg/mL (panel b). Remaining activities in the presence of extracts are expressed as a percentage of enzyme activity incubated in DMSO alone
and are the mean ± SE of three separate determinations. 10 mM Acarbose was used as specific inhibitor of α-glucosidase
Fig. 3 Inhibition of β-glucosidase by extracts 10, 14 and 15. β-
Glucosidase was incubated with extracts at a concentration of 1 mg/mL.
Remaining activities in the presence of extracts are expressed as a
percentage of enzyme activity incubated in DMSO alone and are
the mean ± SE of three separate determinations. 1 M Isofagomine
was used as specific inhibitor of β-glucosidase
Fig. 4 Inhibition of α-glucosidase by subfractions separated from extracts
14 (panel a) and 10 (panel b). α-Glucosidase was incubated with extracts
at a concentration of 1 mg/mL. Remaining activities in the presence of
extracts are expressed as a percentage of enzyme activity incubated in
DMSO alone and are the mean ± SE of three separate determinations.
10 mM Acarbose was used as specific inhibitor of α-glucosidase
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is only preliminary experiments performed to verify
the absence of intrinsic toxicity of the products stud-
ied. Data need to be reproduced on pancreatic cells.
Preliminary screening of raw extracts on α-glucosidase
activity
The two extracts from N. diderrichii (E 14 and E 15)
and the one from S. pobeguinii (E 10) were tested for
their capacity to inhibit α-glucosidase. The extracts
from N. diderricchii were very potent α-glucosidase
inhibitors and totally impede the enzymatic activity at
1 mg/mL concentration (Fig. 2a). Both still retained a
high activity at 0.1 mg/mL (Fig. 2b), the leaf extract
(E 14) being more active than the bark extract (E 15).
Tested in the same conditions, extract 10 isolated
from S. pobeguinii was less active (45 and 0 % inhibition
at 1 and 0.1 mg/mL). Finally, the inhibiting capacity of the
most active samples (E14 and E 15) was severely reduced
at 0.01 mg/mL (see Additional file 2).
Nevertheless, it is noteworthy that the extracts from
N. diderrichii (E 14 and E 15) displayed a higher inhibi-
tory potency than the reference compound acarbose,
which is an oral medication used to treat type 2 diabetes.
Indeed, E14, which induced 100 % inhibition at 0.1 mg/
mL, was more than 60 fold more active than Acarbose
(63 % inhibition at 10 mM final concentration =
6.45 mg/mL).
The high activity observed for the extract obtained
from of N. diderrichii leaves (E 14), which is the richest
in phenolic components, suggests a direct relationship
between its inhibitory potential of α-glucosidase and its
content in phenolic compounds.
Selective inhibition by raw extracts
We further evaluated the inhibitory potential of raw ex-
tracts on the β-hydrolysis of glucopyranosides to ascer-
tain the stereospecificity of the active compounds.
Evaluation of inhibitory efficiency of the three extracts
on β-glucosidase indicated a moderate activity of E 14
and E 15 at 1 mg/mL (with a maximal inhibition of 62
and 37 %) while E 10 did not inhibit at all the enzyme at
this concentration (Fig. 3). When decreasing the concen-
trations, the inhibitory effect was almost completely lost
at 0.01 mg/mL (see Additional file 3). Clearly, even at
the higher concentration, the extracts were much less ef-
ficient than isofagomine.
Fractionation of extracts and screening on α-glucosidase
activity
To go further in the identification of active compounds,
the most efficient raw extract from N. diderrichii (E 14,
Fig. 4a) and that from S. pobeguinii (E 10, Fig. 4b) were
submitted to preparative HPLC in order to evidence the
most efficient fractions by biological evaluation (see Add-
itional files 4 and 5). The subfractions were tested on α-
glucosidase activity and compared to the raw extracts 10
and 14. The head hydrophilic fractions as well as the
queue lipophilic fractions displayed a moderate inhibitory
potency at a concentration of 1 mg/mL, whereas fractions
Fig. 5 Inhibition of α-glucosidase by extracts 10 and 14 and by the most active subfractions tested at 1, 0.1 and 0.01 mg/mL (from left to right).
Remaining activities in the presence of extracts are expressed as a percentage of enzyme activity incubated in DMSO alone and are the mean ± SE
of three separate determinations. 10 mM Acarbose was used as specific inhibitor of α-glucosidase
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10.10 and 10.11 as well as 14.8-14.11 showed the highest
activity against α-glucosidase (Fig. 4).
These results have been corroborated by testing the
active fractions at concentrations 1.0, 0.1 and 0.01 mg/mL;
extract 14 remained more efficient than extract 10. The
most active fractions were F 10.10, F 14.9 and F14.10,
which still show very potent inhibitory effect at 0.1 mg/mL
(78-93 % inhibition) (Fig. 5).
Conclusion
The present study clearly indicates that compounds
present in extracts of N. diderrichii (E 14 and E 15) and
S. pobeguinii (E 10) are potent and selective inhibitors of
α-glucosidase. A comparison with the results obtained
with acarbose, which is used as oral medication to treat
type 2 diabetes, indicates that the most active extract,
obtained from N. diderrichii leaves, is more than 60-fold
more active than the commercial antidiabetic drug. In
addition, at the concentration inducing the highest effect
on α-glucosidase inhibition, no toxicity was observed on
human cell line. This demonstrates the safety of these
extracts and permits to allow their use.
Recently, extracts with high phenolic contents have
shown a strong capacity to inhibit α-glucosidase activ-
ity [54–56] and to treat diabetic rats [57]. The same
correlation is observed in our study, the most active
extract (E14), obtained from N. diderrichii leaves, be-
ing also the richest in phenols. Therefore, we can
postulate that the antidiabetic activity of N. diderrichii
and S. pobeguinii extracts might be related to their
phenolic compounds content, even if we cannot ex-
clude the participation of other classes of compounds.
Finally, our results validate the folk medicinal use of S.
pobeguinii and N. diderrichii for their hypoglycemiant
effect. Since these plants are widely available in Gabon, they
could be a source of cheap and effective medication for
persons with high blood glucose levels.
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